Clark Stephen S
Known title: Chief People OfficerCIK: 0001632531
Clark Stephen S's purchase track record
Clark Stephen S has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/11/2026 | AMRZ | $249K | pending | pending | — |
| 5/5/2026 | AMRZ | $114 | -2.6% | pending | — |
| 8/15/2025 | AMRZ | $259K | -5.0% | +14.5% | +6.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMRZ | ▲ Buy | Open Market | 5,260 | $249K | 8/11/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 2 | $114 | 5/5/2026 | View on chart |
| AMRZ | ▲ Buy | Open Market | 100 | $5K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 301 | $16K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,040 | $54K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 500 | $26K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,100 | $57K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 400 | $21K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 1,000 | $52K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 70 | $4K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 22 | $1K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 100 | $5K | 8/15/2025 | View on chart |
| AMRZ | ▲ Buy | Open Market | 367 | $19K | 8/15/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JP Morgan cuts Amrize price target to $48, maintains Neutral
JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.
JP Morgan cuts Amrize price target to $48, maintains Neutral. JP Morgan has lowered its price target for Amrize to $48 while keeping a Neutral rating. This move comes as the company prepares to announce its third-quarter 2026 financial results. Recent reports also highlight the firm's regional scale and pricing power, though the current analyst target sits below the average consensus of $47.20.